Langerhans cell histiocytosis (LCH) is a rare pre-malignant disease that can affect children and may have a lethal outcome. Researchers from Immunology and Pediatrics have made a strong argument that driver mutation in a hematopoietic progenitor lies at the origin of both localized and disseminated LCH disease forms. These findings have been published in the scientific journal Blood and are featured on the cover.
LUMC and company Genmab start research to optimally target multiple receptors on T cells to improve immunotherapy.
In a new collaborative project, the Arens lab and Genmab will investigate which combinations of receptors on T cells must be manipulated to optimally enhance immunotherapy against cancer and infection. More than 900,000 euros has been released by Genmab for the research.
Looking for information on one of our topics, a new place to conduct your research or connect to experienced researchers to join forces with? Feel free to contact us!